Close
Solutions
Online Inquiry
Global Services

One-Stop CAR-T Therapy Development

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Services Platforms Advantages Resources Related Sections

Immunotherapy has become a revolution in the area of cancer treatment. Compared to the traditional methods, such as invasive surgeries, radiation and chemotherapy, immunotherapy is more specific and less toxic to patients. Chimeric antigen receptor (CAR)-engineered T cell therapy is the most promising approach, which has shown remarkable ability to eliminate various kinds of tumors, especially for B cell malignancies, with up to 95% response rates and durable complete remission. A CAR mainly consists of a single chain variable fragment (scFv) from a monoclonal antibody which binds a specific antigen, a hinge and spacer element, a trans-membrane region and an internal signaling domain such as CD3ζ. The main advantage of CAR-T cell is that it bypasses MHC restriction, which allows for direct activation of effector cells for the treatment of various types of tumors.

Creative Biolabs is a world-renowned service provider for immunotherapy. We have one of the world's largest collection of CAR products of different generations targeting various biomarkers, and we continue to innovate the next generation CAR technologies to achieve even greater results. Based on advanced technology and years of research, Creative Biolabs offers high-quality custom service covering the entire CAR-T therapy development process to best suit your technical, program and budget requirements which can greatly assist your research, preclinical investigation and clinical stage development.

CAR-T Therapy Development Solutions

Biomarker Identification & Selection High Affinity ScFv Generation CAR Design & Construction Virus Packaging & CAR Gene Delivery CAR-T In Vitro Assay CAR-T Preclinical In Vivo Assay CAR-T Clinical Trial
Biomarker Identification & Selection
  • De novo discovery of potential cancer biomarkers by multiple gene and protein analysis technologies
  • Selection of the most suitable CAR-T therapy targets with greater potency and lower toxicity
High Affinity ScFv Generation
  • In-house inescapable antibody sequence data base
  • A collection of over 6000 antibody products
  • Antibody discovery by hybridomas, mouse, rabbit and human library
  • ScFv sequencing and NGS of hybridomas or phage libary
  • ScFv affinity measurement and optimization
CAR Design & Construction
  • Design and construction of CARs of different generation
  • Smart™ CAR platform for the next generation CAR discovery
  • Customized lentiviral or retroviral CAR construction
Virus Packaging & CAR Gene Delivery
  • High titer transduction-ready pseudoviral particles produced by our cell manufacture platform
  • GMP virus manufacturing for clinical trials and applications
  • Strict quality control
  • Various transfection technology available
  • Transfection method tailored for different cell types
CAR T in Vitro Assay
  • CAR expression validation
  • CAR-T cell proliferation
  • Multiplex cytokine screening
  • Cytotoxicity test against target cells
CAR T Preclinical in Vivo Assay
  • Construction of Xenograft Animal Model
  • Efficacy Test of CAR-T cells
  • Viability and Bio-distribution Study of CAR-T cells
  • Toxicity Evaluation of CAR-T cells
  • GLP-compliant assays
CAR T Clinical Trial
  • Study design and filing
  • Project management and execution
  • Data management and biostatistics
  • QA&QC

CAR-T Cell Platforms

Despite the classical 1st-4th generations of CARs, our Smart™ CAR platform allows to provide construction services of novel CAR designs, such as Dual CAR, TriCAR, Modular CAR, Logic-gated CAR.

Smart™ CAR Construction

We have established a safer approach to cell therapy through the transient expression and non-viral delivery of one or more mRNA molecules into PBMCs or isolated immune cells.

mRNA-Based CAR Cell Platform

We can carry out scFv generation from hybridoma cell line through the converting full immune globulin into a scFv using a short flexible linker or phage display library.

CAR-T Cell Display Platform

Such methods include knocking out endogenous genes to construct allogeneic universal CAR-T cells, destroying inhibitory receptors and integration of the CAR cassette.

CRISPR-edited CAR Cell Technology

This technology platform provides an unlimited source of engineered stem cell-derived CAR-T/NK/MA immune cells to eliminate cancer cells or regulate the tumor microenvironment.

CAR-Stem Cell Platform

Highlights & Advantages

  • Fully custom services are adapted according to your project.
  • One-stop solutions from biomarker discovery, CAR cell production, to preclinical/clinical validation.
  • Available to construct the classical, novel, and special CAR designs, and easily to submit a custom CAR design online with a few clicks.
  • Professional team with extensive experience in cell engineering, supporting you at every stage of your project.

Resources

Use the resources in our library to help you understand your options and make critical decisions for your study.

VideosPodcastsInfographicFlyer Support Knowledge
Overview of Chimeric Antigen Receptors

Chimeric antigen receptor (CAR) can combine the extracellular antigen recognition domain from antibodies with the immune cell signaling domain to redirect T cell specificity and induce potent antitumor activity. CAR is an artificial transmembrane receptor that connects the extracellular antigen recognition domain, hinge domain (HD), transmembrane domain (TMD), and intracellular signal transduction domain in series.

Overview of CAR-T Cell Therapies

CAR-T cell therapies revolutionize cancer treatment by harnessing the power of a patient's immune cells. Engineered with chimeric antigen receptors (CARs), these cells effectively target and destroy cancer cells, offering a personalized and potent approach. This groundbreaking immunotherapy has shown remarkable success in treating certain blood cancers, providing hope for patients who may not respond to traditional treatments. CAR-T cell therapies mark a significant stride towards precision medicine, ushering in a new era in oncology with the potential to transform the landscape of cancer care.

T Cell-based Immunotherapies

Based on the significant roles of T cells in the immune system, many small-molecule drugs targeting T cells and T-cell based immunotherapies have been developed for the treatment of intractable diseases including autoimmune diseases and cancer. T cell-based immunotherapies mainly utilize the mechanisms of T cell-mediated immune responses and the effects of some other immune cells such as dendritic cells (DCs), natural killer (NK) cells, and macrophages.

Adoptive Transfer of Genetically Engineered T Cells

Adoptive cell transfer (ACT) of engineered T cells is a cutting-edge therapeutic approach revolutionizing cancer treatment. This innovative method involves modifying T cells, a key component of the immune system, to enhance their ability to target and eliminate cancer cells. By introducing genetically engineered T cells into patients, researchers aim to bolster the immune response against cancer, offering a personalized and potentially curative treatment option. This groundbreaking technology holds promise for addressing various malignancies and represents a significant stride towards more effective and precise cancer therapies.

Related Sections

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.